Somatuline® Depot Acromegaly Answers Webinars
You can watch live events and archived webinars. If you want to watch a webinar, just click on a link below.
Recorded Webinars
To view a Recorded Webinar, you need to register. Registration is free and easy. If you have not registered, do it today.
Note: Remember that you will not be able to interact or submit a question during an archived webinar. However, you will have the ability to start, stop and pause.
Webinar 1 Archive
If you are already registered, you can view Webinar 1:
Acromegaly: Understanding its Physical and Emotional Impact
Presenters:
John D. Carmichael, MD
Karen Sadler, RN, BSN
Status
Webinar 2 Archive
If you are already registered, you can view Webinar 2:
Acromegaly: Getting the Facts on Reimbursement and Dispelling the Myths
Presenters:
Caroline Howard, Regional Account Manager for Managed Care
Kimberly Shumake, Patient Care Liaison
Status
Webinar 3 Archive
If you are already registered, you can view Webinar 3:
Acromegaly: Optimizing Disease Management
Presenters:
Joseph Pinzone, MD, MBA
Kathleen Schweinsberg, RN
Status
Important Indication and Safety Information
Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline® Depot (lanreotide) Injection may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.
Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline® Depot (lanreotide) Injection 60mg.
There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline® Depot (lanreotide) Injection should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.
Somatuline® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.
Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline® Depot (lanreotide) Injection may reduce the intestinal absorption of co-administered drugs. Caution should be used.
The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.
Please see Full Prescribing Information for additional important information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Privacy Policy | Terms & Conditions | SomatulineDepot.com